NDAORALTABLET
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
GLYXAMBI (empagliflozin and linagliptin) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2015.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLYXAMBI is a fixed-dose combination tablet containing empagliflozin (SGLT2 inhibitor) and linagliptin (DPP-4 inhibitor) approved for type 2 diabetes management. It works by blocking sodium-glucose cotransporters in the kidney to increase glucose excretion while inhibiting dipeptidyl peptidase-4 to enhance incretin activity. The combination targets multiple pathways to improve glycemic control in patients inadequately controlled on monotherapy or as add-on treatment.
$137MPart D
PeakStable
11.3 years to LOEGLYXAMBI operates at peak revenue in a competitive SGLT2i space dominated by Boehringer Ingelheim's flagship JARDIANCE; team focus is on defending market share and managing multi-product portfolios rather than launch intensity.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Started Feb 2013
607 enrolled
Diabetes Mellitus, Type 2
Why This Matters for Your Career
Worked on GLYXAMBI at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.